This finding together with the previous functional studies that showed “addiction” of KRAS-mutated cancers to autophagy [91,92,93] suggests that further patient stratification based on molecular alterations is required to fully evaluate the biomarker potential of LC3B in different cancers. The gene discussed is KRAS; the disease is cancer.